Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1058 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2025. Written by Zachary Buxo and 1 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA. Major MEDLINE topics: Cost Savings, Otolaryngology, Drug Industry, Drug Costs. Cited 1 times so far (Crossref); 8 references.
Abstract (original language)
The persistent challenge of high pharmaceutical prices has led to the emergence of vertically integrated direct‐to‐consumer distributors like Mark Cuban Cost Plus Drug Company (MCCPDC). This study aims to evaluate a cost‐saving alternative method for medication sourcing. The most frequently prescribed medications by otolaryngologists were identified through analysis of Medicare Part D data, utilizing prescriber type as a filter. Medications were assessed for availability on the MCCPDC website and drug form consistency. Cost analysis was conducted comparing current pharmaceutical spending against MCCPDC pricing. Potential otolaryngology‐driven savings were estimated at $55.6 million and $1 billion if in effect across all specialties. Our findings suggest considerable potential savings for Medicare by purchasing generic medications at MCCPDC prices.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otolaryngology-Head and Neck Surgery, Wayne State University School of Medicine, Detroit, Michigan, USA.
ORCID profiles: Zachary Buxo
Cite
APA
Buxo, Z., & D Cramer, J. (2025). Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1058
Vancouver
Buxo Z, D Cramer J. Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1058
BibTeX
@article{Buxo2025,
author = {Buxo, Zachary and D Cramer, John},
title = {Potential Cost‐Saving Model Utilizing Mark Cuban Cost Plus Drug Company for Purchasing Common Otolaryngology Medications},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1058}
}
EUVIMED